China CDE Grants CMG901 Breakthrough Therapy Designation for Claudin 18.2-Positive Advanced Gastric & Gastroesophageal Junction Cancer

CMG901 is a Claudin 18.2-targeted antibody-drug conjugate (ADC) developed for the treatment of Claudin 18.2-expressing solid tumors.